HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

NCT05176691 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped HUTCHMED has decided to discontinue the HMPL 760 study.

Conditions

CLL/SLL
NHL
MCL
MZL
Lymphoplasmacytic Lymphoma
Waldenstrom Macroglobulinemia
Follicular Lymphoma
DLBCL
Richter Syndrome

Interventions

DRUG: HMPL-760

Sponsor

Hutchmed